]>
IRCT20251014067632N1 IRCT 2026-04-28 Ahvaz University of Medical Sciences effect of bimatoprost on alopecia areata comparison of the effect of combined intralesional Triamcinolone with topical Bimatoprost versus intralesional Triamcinolone or topical Bimatoprost in the treatment of alopecia areata 2026-02-03 anticipated 42 Recruiting https://irct.ir/trial/88941 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Using the randomization method, patients are divided into three groups. A sealed envelope site is used to divide patients, and randomization is performed in blocks, and each block consists of 6 patients and includes 2 groups A, 2 groups B, and 2 groups C. In order to eliminate the effect of the interpretation of the researcher and the performing physician, in addition to observing blinding, the technique of concealing the allocation of numbers and letters was used, and the names of the groups were hidden, Blinding description: The physician evaluating the results will be unaware of the treatment method used. At the beginning of treatment and one month after the last session, photographs of the lesions will be taken using a Xiaomi Redmi note11 pro mobile phone at a distance of 30 cm. 3 alopecia areata. Intervention 1: Control group: was treated with intralesional triamcinolone injection (5mg/ml for scalp alopecia and 2.5mg/ml for facial alopecia) monthly for three months. Intervention 2: Intervention group:Under treatment with bimatoprost 0.01% every 12 hours for three months. Intervention 3: Intervention group: Under combination treatment of monthly triamcinolone injections and topical bimatoprost every 12 hours for three months. Yes - There is a plan to make this available What will be shared: Research data, including anonymized consent forms and before-and-after photos of patients' results, along with basic information including gender and age, will be shared. When: Access begins 6 months after publication of the article. To whom: Only for researchers working in academic and scientific institutions Conditions: To conduct further studies in this field or other parallel and related studies. Where to obtain: To receive the documents, please send a request to Dr. Negin Sozengar's email: negin.sgr@gmail.com. If there is no response, please send a request to the address: Dermatology Department Office, 3rd Floor, Imam Hospital, Azadegan Street, Ahvaz, Khuzestan. How to obtain: After registering the request in writing, along with the phone number and details of the applicant, to the email or address mentioned, a response will be received within one week after the necessary checks. The reason for requesting the documents should also be mentioned. Comments:
public Negin Soozangar
Unit 10, 5th floor, asadi8 complex, No.2009, daneshjoo 48 street, daneshgah town, ahvaz
Ahvaz Iran (Islamic Republic of) 6134933357 +98 61 3292 1837 negin.sgr@gmail.com Ahvaz University of Medical Sciences scientific Negin Soozangar
Unit 10, 5th floor, asadi8 complex, No.2009, daneshjoo 48 street, daneshgah town, ahvaz
Ahvaz Iran (Islamic Republic of) 6134933357 +98 61 3292 1837 negin.sgr@gmail.com Ahvaz University of Medical Sciences Iran (Islamic Republic of)  People over 18 years of age with the hair loss pattern of alopecia areata who have at least one or more patches of alopecia.  Consent to participate in the study. 18 years no limit Both  Sensitivity to the medications used.  Pregnancy and breastfeeding.  Systemic treatment has been performed within the past 3 months or topical treatment has been performed within the past 2 weeks.  The site of application of the medicine is infected.  Patients with pattern universalis or ophiasis or totalis  Patients with spontaneous hair regrowth in the area of ​​hair loss  Patients with other dermatological diseases simultaneously L63 Alopecia areata Treatment - Drugs Treatment - Drugs Treatment - Drugs Control group: was treated with intralesional triamcinolone injection (5mg/ml for scalp alopecia and 2.5mg/ml for facial alopecia) monthly for three months. Intervention group:Under treatment with bimatoprost 0.01% every 12 hours for three months Intervention group: Under combination treatment of monthly triamcinolone injections and topical bimatoprost every 12 hours for three months Amount of change in the SALT score (from 0 to 100). Timepoint: At the beginning of treatment and one month after the end of treatment. Method of measurement: According to the areas involved in the scalp /left side:18% , right side=18%)/ ,top=40%,back=24 / (S0=no hair loss/ s1=<25% hair loss/ s2= 25%-49% hair loss/ s3=50%-74% hair loss/ s4=75-99%hairloss/ s5=100% total scalp hair loss). Changes in dermoscopy findings. Timepoint: At the beginning of treatment and one month after the end of treatment. Method of measurement: Based on the researcher's observation (determining the number of black dots, yellow dots, broken hairs, exclamation mark hairs, villous hairs). Checking the rate of change in GPA score. Timepoint: At the beginning of treatment and one month after the end of treatment. Method of measurement: Evaluation of patient outcomes by a physician outside the study based on the response rate to treatment using photographs taken before and one month after treatment (from 0 to 4) (A0 = no improvement / A1 = poor response <25% / A2 = good response 25 to 50% / A3 = very good response 50 to 75% / A4 = excellent response 75 to 100%). Ahvaz University of Medical Sciences Approved 2024-10-28 Ethics Committee of Ahvaz Jundishapur University of Medical Sciences No.2004, Unit 10, 5th Floor, Asadi8 Complex, 48 Daneshjoo St., daneshgah Town ahwaz Khouzestan Iran (Islamic Republic of)